A Phase IIa Study of Z-207 in Patients with Seasonal Allegic Rhinitis - Investigation of the Efficacy and Safety of Z-207 after Single Injection
Phase 2
- Conditions
- Seasonal Allergic Rhinitis
- Registration Number
- JPRN-jRCT2080221241
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Patient with history of moderate to sever seasonal allergic rhinitis for at least 2 years
Patient with positive reaction for Radio Allergen Sorbent Test using Japanease ceder pollen
Patient exhibit both a total nasal symptom score of at least 4, and a nasal obstruction score of at least 2 under exposure to allergen using pollen challenge chamber ( Total nasal symptom score is the sum of sneezing, nasal discharge, nasal obstruction which has been scored on a scale from 0 to 4 )
Exclusion Criteria
Patient with positive reaction for Radio Allergen Sorbent Test for house dust mite
Patient with positive reaction for Radio Allergen Sorbent Test for orchard grass pollen
Patient who never received medical drug therapy for allergic rhinitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total nasal symptom score under exposure to allergen using pollen challenge chamber, and nasal symptom score natural exposure to allergen during the pollen season
- Secondary Outcome Measures
Name Time Method